Publicaciones en colaboración con investigadores/as de Claude Bernard University Lyon 1 (14)

2020

  1. Procedural and Short-Term Results With the New Watchman FLX Left Atrial Appendage Occlusion Device

    JACC: Cardiovascular Interventions, Vol. 13, Núm. 23, pp. 2732-2741

  2. Prognostic gene expression signature for high-grade serous ovarian cancer

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250

2019

  1. Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma

    Journal of Clinical Oncology

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

  2. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis

    The Lancet Haematology, Vol. 5, Núm. 8, pp. e359-e367

2017

  1. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

    Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481

2016

  1. Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial

    Journal of Clinical Oncology, Vol. 34, Núm. 22, pp. 2575-2582

2014

  1. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma

    Blood

  2. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma

    Cancer Treatment Reviews, Vol. 40, Núm. 9, pp. 1080-1088

2013

  1. Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma

    Haematologica, Vol. 98, Núm. 3, pp. 357-363

2012

  1. Guidelines for the use and interpretation of assays for monitoring autophagy

    Autophagy, Vol. 8, Núm. 4, pp. 445-544

2011

  1. PSICQUIC and PSISCORE: Accessing and scoring molecular interactions

    Nature Methods

  2. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial

    The Lancet, Vol. 377, Núm. 9759, pp. 42-51

2010

  1. International network of cancer genome projects

    Nature, Vol. 464, Núm. 7291, pp. 993-998